And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

David Ramsay Biography and Net Worth

Director of La Jolla Pharmaceutical

Mr. Ramsay has been a Director of EXUMA since January 2017. In 2018, Mr. Ramsay served as Senior Vice President and Chief Financial Officer of Bonti, Inc. Mr. Ramsay retired from Halozyme Therapeutics, Inc. (NASDAQ: HALO) in July 2015, where he served as Chief Financial Officer since May 2013 and from 2003 to May 2009. He also served as Halozyme’s Vice President, Corporate Development from May 2009 to May 2013. From 2000 to 2003, Mr. Ramsay was Vice President, Chief Financial Officer of Lathian Systems, Inc., a provider of technology-based sales solutions for the life science industry. From 1998 to 2000, he was with Valeant Pharmaceuticals International, Inc. (formerly ICN Pharmaceuticals, Inc.), where he served as Vice President, Treasurer and Director, Corporate Finance. Mr. Ramsay began his career at Deloitte & Touche, where he obtained his CPA license. Mr. Ramsay also serves on the boards of Savara Pharmaceuticals (NASDAQ: SVRA) and La Jolla Pharmaceutical (NASDAQ: LJPC).

Mr. Ramsay holds a B.S. in business administration from the University of California, Berkeley and a M.B.A. with a dual major in finance and strategic management from The Wharton School at the University of Pennsylvania.

What is David A. Ramsay's net worth?: The estimated net worth of David A. Ramsay is at least $0.00 as of May 24th, 2023. Mr. Ramsay owns 2,151,142 shares of La Jolla Pharmaceutical stock worth more than $0 as of April 19th. This net worth estimate does not reflect any other investments that Mr. Ramsay may own. Learn More about David A. Ramsay's net worth.
How do I contact David A. Ramsay?: The corporate mailing address for Mr. Ramsay and other La Jolla Pharmaceutical executives is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. La Jolla Pharmaceutical can also be reached via phone at (617) 715-3600 and via email at [email protected]. Learn More on David A. Ramsay's contact information.
Has David A. Ramsay been buying or selling shares of La Jolla Pharmaceutical?: David A. Ramsay has not been actively trading shares of La Jolla Pharmaceutical during the past quarter. Most recently, on Monday, December 6th, David A. Ramsay bought 10,000 shares of La Jolla Pharmaceutical stock. The stock was acquired at an average cost of $3.82 per share, with a total value of $38,200.00. Learn More on David A. Ramsay's trading history.

David A. Ramsay Insider Trading History at La Jolla Pharmaceutical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/6/2021	Buy	10,000	$3.82	$38,200.00
12/3/2021	Buy	4,399	$3.66	$16,100.34
5/24/2021	Buy	20,000	$3.49	$69,800.00	51,000
8/24/2020	Buy	47,000	$3.99	$187,530.00

David A. Ramsay Buying and Selling Activity at La Jolla Pharmaceutical

La Jolla Pharmaceutical Company Overview

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.

Today's Range

Now: N/A

50 Day Range

MA: $5.73

$3.12

$6.22

2 Week Range

Now: N/A

Volume

66,708 shs

Average Volume

158,476 shs

Market Capitalization

$155.11 million

P/E Ratio

51.84

Dividend Yield

N/A

Beta

2.39

He Is Giving Away Bitcoin

From Crypto Swap Profits | Ad

>> Register right here